<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab3">
 <label>Table 11.3</label>
 <caption>
  <p>Coronavirus vaccines</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>S. No.</th>
    <th>Platform</th>
    <th>Type of vaccine</th>
    <th>Target virus</th>
    <th>Developer</th>
    <th>Current stage</th>
    <th>References</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>1</td>
    <td>DNA</td>
    <td>INO-4700 DNA plasmid vaccine expresses S protein</td>
    <td>MERS-CoV</td>
    <td>Inovio Pharmaceuticals</td>
    <td>Clinical trial phase 2</td>
    <td>
     <ext-link ext-link-type="uri" xlink:href="http://inovio.com" xmlns:xlink="http://www.w3.org/1999/xlink">Inovio.com</ext-link>
    </td>
   </tr>
   <tr>
    <td>2</td>
    <td>DNA</td>
    <td>GLS-5300</td>
    <td>MERS-CoV</td>
    <td>GeneOne Life Science and Inovio</td>
    <td>Clinical trial phase 1</td>
    <td>Shen et al. (
     <xref ref-type="bibr" rid="CR20">2019</xref>)
    </td>
   </tr>
   <tr>
    <td>3</td>
    <td>Vector (adeno virus)</td>
    <td>ChAdOx1 S protein antigen</td>
    <td>MERS CoV</td>
    <td>University of Oxford</td>
    <td>Clinical trial phase 1</td>
    <td>Alharbi et al. (
     <xref ref-type="bibr" rid="CR2">2017</xref>)
    </td>
   </tr>
   <tr>
    <td>4</td>
    <td>Vector</td>
    <td>Ad5-SARS-CoV vectors</td>
    <td>SARS-CoV</td>
    <td>University of Pittsburgh</td>
    <td>Animal trial</td>
    <td>Gao et al. (
     <xref ref-type="bibr" rid="CR12">2003</xref>)
    </td>
   </tr>
   <tr>
    <td>5</td>
    <td>Live attenuated</td>
    <td>UV-inactivated purified SARS-CoV</td>
    <td>SARS-CoV</td>
    <td>National Institute of Infectious Diseases Japan</td>
    <td>Subclinical</td>
    <td>Takasuka et al. (
     <xref ref-type="bibr" rid="CR22">2004</xref>)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
